CytoSorbents Reports the First Patient Enrollment of DrugSorb-ATR Antithrombotic Removal System in the (STAR-D) Trial During Cardiac Surgery
Shots:
- The first patient has been enrolled in the US (STAR-D) trial to evaluate the intraoperative use of the DrugSorb-antithrombotic removal system in ~120 patients to remove apixaban and rivaroxaban during cardiothoracic surgery across 30 sites in the US. The patient was enrolled at Virginia Commonwealth University’s Pauley Heart Center
- If the results were found to be positive, DrugSorb-ATR will be a safe and easy to implement the solution to help cardiac surgeons globally
- In Aug 2021, DrugSorb-antithrombotic removal system has received BTD from the US FDA for the removal of DOACs apixaban and rivaroxaban to reduce the risk of serious perioperative bleeding from cardiothoracic surgery
Ref: PRNewswire | Image: Cytosorbents
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
